Beginning next week, Finland will roll out bird flu vaccinations for 10,000 individuals, aged 18 or over, who are at increased risk of contracting avian influenza due to the nature of their work or other circumstances. This comes after the Nordic country culled approximately 485,000 animals to control the virus outbreak on minx and fox fur farms last year.
In a world first, Finland is set to roll out bird flu vaccinations for humans next week, targeting workers who are most exposed to animals. This proactive measure involves vaccinating 10,000 individuals, each receiving two doses, as part of a broader EU effort that includes up to 40 million doses across 15 countries.
CSL Seqirus, the Australian pharmaceutical company behind the vaccines, confirmed that Finland will be the first to launch this vaccination strategy. CSL Seqirus is one of the world’s largest influenza vaccine companies.
CSL Seqirus will deliver approximately 4.8 million doses of the vaccine as part of the National Pre-Pandemic Influenza Vaccine Stockpile program for the USA.
Also the European Commission’s Health Emergency Preparedness and Response Authority (HERA) tapped CSL Seqirus to deliver 665,000 doses of its pre-pandemic bird flu vaccine for 15 European countries. Under a four-year contract, authorities can purchase up to 40 million more doses.
The vaccine AUDENZ™ - Adjuvanted Cell-based Monovalent Influenza A (H5N1) Vaccine is said to be well-matched to the H5 of the currently circulating H5N1 strain,
In a world first, Finland is set to roll out bird flu vaccinations for humans next week, targeting workers who are most exposed to animals. This proactive measure involves vaccinating 10,000 individuals, each receiving two doses, as part of a broader EU effort that includes up to 40 million doses across 15 countries.
CSL Seqirus, the Australian pharmaceutical company behind the vaccines, confirmed that Finland will be the first to launch this vaccination strategy. CSL Seqirus is one of the world’s largest influenza vaccine companies.
CSL Seqirus will deliver approximately 4.8 million doses of the vaccine as part of the National Pre-Pandemic Influenza Vaccine Stockpile program for the USA.
Also the European Commission’s Health Emergency Preparedness and Response Authority (HERA) tapped CSL Seqirus to deliver 665,000 doses of its pre-pandemic bird flu vaccine for 15 European countries. Under a four-year contract, authorities can purchase up to 40 million more doses.
The vaccine AUDENZ™ - Adjuvanted Cell-based Monovalent Influenza A (H5N1) Vaccine is said to be well-matched to the H5 of the currently circulating H5N1 strain,
